News

CTP-656 is a novel deuterium-modified version of ivacaftor. Ivacaftor is commercially available under the name Kalydeco®. The clinical trial results continue to support the development of CTP-656 as

BiCNU is primarily used for chemotherapy in the treatment of several types of brain cancer, multiple myeloma and lymphoma (Hodgkin’s and non-Hodgkin). BiCNU is also sometimes used for

TAF is a novel targeted prodrug of tenofovir that has showed high antiviral efficacy similar to and at a dose less than one-tenth that of Gilead’s Viread (tenofovir

The regulator has however asked Acadia to include a boxed warning on the drug’s label for an increased risk of death associated with its use in older people.

The enrollment in the US has reached 36 patients, exceeding the minimum of 30 patients proposed by the United States Food and Drug Administration (FDA). The last patient

ALKS 7119 is being developed for the treatment of agitation in patients with Alzheimer’s disease and other central nervous system (CNS) indications. Based on initial blinded data from

The facility will supply RNAi therapeutics for Alnylam’s clinical and commercial needs. The location, selected in close collaboration with Commonwealth and local officials, demonstrates Alnylam’s ongoing commitment to

Therabron Therapeutics’ lead biopharmaceutical product candidate is a proprietary preparation of recombinant human CC10 protein which has potential clinical applications, based on its potent anti-inflammatory properties, in a

The deal gives AbbVie rights to Stemcentrx’s experimental treatment for a form of lung cancer and other experimental drugs. Stemcentrx’s lead late-stage asset rovalpituzumab tesirine (Rova-T) is presently